Type-2 diabetes-induced changes in vascular extracellular matrix gene expression

Relation to vessel size

Wei Wei Song, Adviye Ergul

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background: Hyperglycemia-incluced changes in vascular wall structure contribute to the pathogenesis of diabetic microvascular and macrovascular complications. Matrix metalloproteinases (MMP), a family of proteolytic enzymes that degrade extracellular matrix (ECM) proteins, are essential for vascular remodeling. We have shown that endothelin-I (ET-I) mediates increased MMP activity and associated vascular remodeling in Type 2 diabetes. However, the effect of Type 2 diabetes and/or ET-I on the regulation of ECM and MMP gene expression in different vascular beds remains unknown. Methods: Aorta and mesenteric artery samples were isolated from control, Type 2 diabetic Goto-Kakizaki (GK) rats and GK rats treated with ET A antagonist ABT-627. Gene expression profile of MMP-2, MMP-9, MTI-MMP, fibronectin, procollagen type I, c-fos and c-jun, were determined by quantitative real-time (qRT) PCR. In addition, aortic gene expression profile was evaluated by an ECM & Adhesion Molecules pathway specific microarray approach. Results: Analysis of the qRT-PCR data demonstrated a significant increase in mRNA levels of MMPs and ECM proteins as compared to control animals after 6 weeks of mild diabetes. Futhermore, these changes were comparable in aorta and mesentery samples. In contrast, treatment with ET A antagonist prevented diabetes-induced changes in expression of MMPs and procollagen type I in mesenteric arteries but not in aorta. Microaarray analysis provided evidence that 27 extracellular matrix genes were differentially regulated in diabetes. Further qRT-PCR with selected 7 genes confirmed the microarray data. Conclusion: These results suggest that the expression of both matrix scaffold protein and matrix degrading MMP genes are altered in macro and microvascular beds in Type 2 diabetes. ET A antagonism restores the changes in gene expression in the mesenteric bed but not in aorta suggesting that ET-I differentially regulates microvascular gene expression in Type 2 diabetes.

Original languageEnglish (US)
Article number3
JournalCardiovascular Diabetology
Volume5
DOIs
StatePublished - Feb 17 2006

Fingerprint

Matrix Metalloproteinases
Type 2 Diabetes Mellitus
Extracellular Matrix
Blood Vessels
Gene Expression
Aorta
Endothelins
Real-Time Polymerase Chain Reaction
Mesenteric Arteries
Extracellular Matrix Proteins
Collagen Type I
Transcriptome
Genes
Mesentery
Matrix Metalloproteinase 2
Matrix Metalloproteinase 9
Fibronectins
Hyperglycemia
Peptide Hydrolases
Messenger RNA

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this

Type-2 diabetes-induced changes in vascular extracellular matrix gene expression : Relation to vessel size. / Song, Wei Wei; Ergul, Adviye.

In: Cardiovascular Diabetology, Vol. 5, 3, 17.02.2006.

Research output: Contribution to journalArticle

@article{dbf6ddf12de040a6b748f64ba7fdc2d8,
title = "Type-2 diabetes-induced changes in vascular extracellular matrix gene expression: Relation to vessel size",
abstract = "Background: Hyperglycemia-incluced changes in vascular wall structure contribute to the pathogenesis of diabetic microvascular and macrovascular complications. Matrix metalloproteinases (MMP), a family of proteolytic enzymes that degrade extracellular matrix (ECM) proteins, are essential for vascular remodeling. We have shown that endothelin-I (ET-I) mediates increased MMP activity and associated vascular remodeling in Type 2 diabetes. However, the effect of Type 2 diabetes and/or ET-I on the regulation of ECM and MMP gene expression in different vascular beds remains unknown. Methods: Aorta and mesenteric artery samples were isolated from control, Type 2 diabetic Goto-Kakizaki (GK) rats and GK rats treated with ET A antagonist ABT-627. Gene expression profile of MMP-2, MMP-9, MTI-MMP, fibronectin, procollagen type I, c-fos and c-jun, were determined by quantitative real-time (qRT) PCR. In addition, aortic gene expression profile was evaluated by an ECM & Adhesion Molecules pathway specific microarray approach. Results: Analysis of the qRT-PCR data demonstrated a significant increase in mRNA levels of MMPs and ECM proteins as compared to control animals after 6 weeks of mild diabetes. Futhermore, these changes were comparable in aorta and mesentery samples. In contrast, treatment with ET A antagonist prevented diabetes-induced changes in expression of MMPs and procollagen type I in mesenteric arteries but not in aorta. Microaarray analysis provided evidence that 27 extracellular matrix genes were differentially regulated in diabetes. Further qRT-PCR with selected 7 genes confirmed the microarray data. Conclusion: These results suggest that the expression of both matrix scaffold protein and matrix degrading MMP genes are altered in macro and microvascular beds in Type 2 diabetes. ET A antagonism restores the changes in gene expression in the mesenteric bed but not in aorta suggesting that ET-I differentially regulates microvascular gene expression in Type 2 diabetes.",
author = "Song, {Wei Wei} and Adviye Ergul",
year = "2006",
month = "2",
day = "17",
doi = "10.1186/1475-2840-5-3",
language = "English (US)",
volume = "5",
journal = "Cardiovascular Diabetology",
issn = "1475-2840",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Type-2 diabetes-induced changes in vascular extracellular matrix gene expression

T2 - Relation to vessel size

AU - Song, Wei Wei

AU - Ergul, Adviye

PY - 2006/2/17

Y1 - 2006/2/17

N2 - Background: Hyperglycemia-incluced changes in vascular wall structure contribute to the pathogenesis of diabetic microvascular and macrovascular complications. Matrix metalloproteinases (MMP), a family of proteolytic enzymes that degrade extracellular matrix (ECM) proteins, are essential for vascular remodeling. We have shown that endothelin-I (ET-I) mediates increased MMP activity and associated vascular remodeling in Type 2 diabetes. However, the effect of Type 2 diabetes and/or ET-I on the regulation of ECM and MMP gene expression in different vascular beds remains unknown. Methods: Aorta and mesenteric artery samples were isolated from control, Type 2 diabetic Goto-Kakizaki (GK) rats and GK rats treated with ET A antagonist ABT-627. Gene expression profile of MMP-2, MMP-9, MTI-MMP, fibronectin, procollagen type I, c-fos and c-jun, were determined by quantitative real-time (qRT) PCR. In addition, aortic gene expression profile was evaluated by an ECM & Adhesion Molecules pathway specific microarray approach. Results: Analysis of the qRT-PCR data demonstrated a significant increase in mRNA levels of MMPs and ECM proteins as compared to control animals after 6 weeks of mild diabetes. Futhermore, these changes were comparable in aorta and mesentery samples. In contrast, treatment with ET A antagonist prevented diabetes-induced changes in expression of MMPs and procollagen type I in mesenteric arteries but not in aorta. Microaarray analysis provided evidence that 27 extracellular matrix genes were differentially regulated in diabetes. Further qRT-PCR with selected 7 genes confirmed the microarray data. Conclusion: These results suggest that the expression of both matrix scaffold protein and matrix degrading MMP genes are altered in macro and microvascular beds in Type 2 diabetes. ET A antagonism restores the changes in gene expression in the mesenteric bed but not in aorta suggesting that ET-I differentially regulates microvascular gene expression in Type 2 diabetes.

AB - Background: Hyperglycemia-incluced changes in vascular wall structure contribute to the pathogenesis of diabetic microvascular and macrovascular complications. Matrix metalloproteinases (MMP), a family of proteolytic enzymes that degrade extracellular matrix (ECM) proteins, are essential for vascular remodeling. We have shown that endothelin-I (ET-I) mediates increased MMP activity and associated vascular remodeling in Type 2 diabetes. However, the effect of Type 2 diabetes and/or ET-I on the regulation of ECM and MMP gene expression in different vascular beds remains unknown. Methods: Aorta and mesenteric artery samples were isolated from control, Type 2 diabetic Goto-Kakizaki (GK) rats and GK rats treated with ET A antagonist ABT-627. Gene expression profile of MMP-2, MMP-9, MTI-MMP, fibronectin, procollagen type I, c-fos and c-jun, were determined by quantitative real-time (qRT) PCR. In addition, aortic gene expression profile was evaluated by an ECM & Adhesion Molecules pathway specific microarray approach. Results: Analysis of the qRT-PCR data demonstrated a significant increase in mRNA levels of MMPs and ECM proteins as compared to control animals after 6 weeks of mild diabetes. Futhermore, these changes were comparable in aorta and mesentery samples. In contrast, treatment with ET A antagonist prevented diabetes-induced changes in expression of MMPs and procollagen type I in mesenteric arteries but not in aorta. Microaarray analysis provided evidence that 27 extracellular matrix genes were differentially regulated in diabetes. Further qRT-PCR with selected 7 genes confirmed the microarray data. Conclusion: These results suggest that the expression of both matrix scaffold protein and matrix degrading MMP genes are altered in macro and microvascular beds in Type 2 diabetes. ET A antagonism restores the changes in gene expression in the mesenteric bed but not in aorta suggesting that ET-I differentially regulates microvascular gene expression in Type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=33645641243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645641243&partnerID=8YFLogxK

U2 - 10.1186/1475-2840-5-3

DO - 10.1186/1475-2840-5-3

M3 - Article

VL - 5

JO - Cardiovascular Diabetology

JF - Cardiovascular Diabetology

SN - 1475-2840

M1 - 3

ER -